130 related articles for article (PubMed ID: 8529408)
1. Anti-leukocyte function-1 antibody treatment prevents the rejection of intraocular regressor tumors and their metastases.
Li XY; Mayhew E; Niederkorn JY
Curr Eye Res; 1995 Aug; 14(8):719-26. PubMed ID: 8529408
[TBL] [Abstract][Full Text] [Related]
2. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors.
Knisely TL; Luckenbach MW; Fischer BJ; Niederkorn JY
J Immunol; 1987 Jun; 138(12):4515-23. PubMed ID: 3108394
[TBL] [Abstract][Full Text] [Related]
3. Role of anti-LFA-1 and anti-ICAM-1 combined MAb treatment in the rejection of tumors induced by Moloney murine sarcoma virus (M-MSV).
Rosato A; Mandruzzato S; Bronte V; Zambon A; Macino B; Calderazzo F; Zanovello P; Collavo D
Int J Cancer; 1995 May; 61(3):355-62. PubMed ID: 7729948
[TBL] [Abstract][Full Text] [Related]
4. Immune rejection of metastases arising from intraocular tumors in mice.
Niederkorn JY; Knisely TL; Mayhew E
Invest Ophthalmol Vis Sci; 1986 Sep; 27(9):1355-61. PubMed ID: 3091527
[TBL] [Abstract][Full Text] [Related]
5. Effect of LFA-1 and ICAM-1 antibody treatment on murine corneal allograft survival.
He Y; Mellon J; Apte R; Niederkorn JY
Invest Ophthalmol Vis Sci; 1994 Jul; 35(8):3218-25. PubMed ID: 7913917
[TBL] [Abstract][Full Text] [Related]
6. Spontaneous immune rejection of intraocular tumors in mice.
Niederkorn JY; Meunier PC
Invest Ophthalmol Vis Sci; 1985 Jun; 26(6):877-84. PubMed ID: 3924853
[TBL] [Abstract][Full Text] [Related]
7. The role of cell adhesion molecules in allograft rejection after penetrating keratoplasty in mice. Clinical and immunohistochemical study.
Yamagami S; Tsuru T; Isobe M; Obata H; Suzuki J
Graefes Arch Clin Exp Ophthalmol; 1996 Jun; 234(6):382-7. PubMed ID: 8738705
[TBL] [Abstract][Full Text] [Related]
8. Effects of anti-intercellular adhesion molecule-1 and anti-lymphocyte-function-associated antigen-1 monoclonal antibodies on the metastasis of murine tumors.
Sun R; Hojo H; Kato K; Hashimoto Y
Invasion Metastasis; 1996; 16(1):39-48. PubMed ID: 8830764
[TBL] [Abstract][Full Text] [Related]
9. Emergence of a dominant cytotoxic T lymphocyte antitumor effector from tumor-infiltrating cells in the anterior chamber of the eye.
Knisely TL; Niederkorn JY
Cancer Immunol Immunother; 1990; 30(6):323-30. PubMed ID: 2302723
[TBL] [Abstract][Full Text] [Related]
10. Effect of anti-intercellular adhesion molecule-1 and anti-leukocyte function associated antigen-1 monoclonal antibodies on rat-to-mouse cardiac xenograft rejection.
Miwa S; Isobe M; Suzuki J; Makuuchi M; Miyasaka M; Yamazaki S; Kawasaki S
Surgery; 1997 Jun; 121(6):681-9. PubMed ID: 9186469
[TBL] [Abstract][Full Text] [Related]
11. Rejection of intraocular tumors from transgenic mice by tumor-infiltrating lymphocytes.
Ma D; Alizadeh H; Comerford SA; Gething MJ; Sambrook JF; Anand R; Niederkorn JY
Curr Eye Res; 1994 May; 13(5):361-9. PubMed ID: 7914482
[TBL] [Abstract][Full Text] [Related]
12. Termination of immune privilege in the anterior chamber of the eye when tumor-infiltrating lymphocytes acquire cytolytic function.
Ksander BR; Mammolenti MM; Streilein JW
Transplantation; 1991 Jul; 52(1):128-33. PubMed ID: 1907041
[TBL] [Abstract][Full Text] [Related]
13. Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and helper T lymphocyte responses.
Niederkorn JY; Streilein JW
J Immunol; 1983 Dec; 131(6):2670-4. PubMed ID: 6196396
[TBL] [Abstract][Full Text] [Related]
14. Direct antigen presentation through binding of donor intercellular adhesion molecule-1 to recipient lymphocyte function-associated antigen-1 molecules in xenograft rejection.
Ohta Y; Gotoh M; Ohzato H; Fukuzaki T; Nishihara M; Dono K; Umeshita K; Sakon M; Yagita H; Okumura K; Tanaka T; Kawashima H; Miyasaka M; Monden M
Transplantation; 1998 Apr; 65(8):1094-100. PubMed ID: 9583871
[TBL] [Abstract][Full Text] [Related]
15. The immunopathology of intraocular tumour rejection.
Niederkorn JY
Eye (Lond); 1991; 5 ( Pt 2)():186-92. PubMed ID: 2070879
[TBL] [Abstract][Full Text] [Related]
16. Immunologic evaluation of spontaneous regression of an intraocular murine melanoma.
Knisely TL; Niederkorn JY
Invest Ophthalmol Vis Sci; 1990 Feb; 31(2):247-57. PubMed ID: 2154414
[TBL] [Abstract][Full Text] [Related]
17. In situ suppression of delayed-type hypersensitivity: another mechanism for sustaining the immune privilege of the anterior chamber.
Benson JL; Niederkorn JY
Immunology; 1991 Sep; 74(1):153-9. PubMed ID: 1937568
[TBL] [Abstract][Full Text] [Related]
18. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
Chen PW; Ksander BR
Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
[TBL] [Abstract][Full Text] [Related]
19. Specific immunosuppression of corneal allograft rejection by combination of anti-VLA-4 and anti-LFA-1 monoclonal antibodies in mice.
Hori J; Isobe M; Yamagami S; Mizuochi T; Tsuru T
Exp Eye Res; 1997 Jul; 65(1):89-98. PubMed ID: 9237869
[TBL] [Abstract][Full Text] [Related]
20. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response.
Cavallo F; Martin-Fontecha A; Bellone M; Heltai S; Gatti E; Tornaghi P; Freschi M; Forni G; Dellabona P; Casorati G
Eur J Immunol; 1995 May; 25(5):1154-62. PubMed ID: 7539748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
